CN1703229B - 治疗前列腺和其他癌的组合物和其制备药物的用途 - Google Patents

治疗前列腺和其他癌的组合物和其制备药物的用途 Download PDF

Info

Publication number
CN1703229B
CN1703229B CN2003801009272A CN200380100927A CN1703229B CN 1703229 B CN1703229 B CN 1703229B CN 2003801009272 A CN2003801009272 A CN 2003801009272A CN 200380100927 A CN200380100927 A CN 200380100927A CN 1703229 B CN1703229 B CN 1703229B
Authority
CN
China
Prior art keywords
hsp27
seq
composition
antisense
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2003801009272A
Other languages
English (en)
Chinese (zh)
Other versions
CN1703229A (zh
Inventor
M·E·格利夫
P·罗基
M·西奈夫斯基
E·贝拉尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of CN1703229A publication Critical patent/CN1703229A/zh
Application granted granted Critical
Publication of CN1703229B publication Critical patent/CN1703229B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2003801009272A 2002-10-02 2003-10-02 治疗前列腺和其他癌的组合物和其制备药物的用途 Expired - Fee Related CN1703229B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41585902P 2002-10-02 2002-10-02
US60/415,859 2002-10-02
US46395203P 2003-04-18 2003-04-18
US60/463,952 2003-04-18
PCT/CA2003/001588 WO2004030660A2 (en) 2002-10-02 2003-10-02 Compositions for treatment of prostate and other cancers

Publications (2)

Publication Number Publication Date
CN1703229A CN1703229A (zh) 2005-11-30
CN1703229B true CN1703229B (zh) 2011-01-05

Family

ID=32073392

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2003801009272A Expired - Fee Related CN1703229B (zh) 2002-10-02 2003-10-02 治疗前列腺和其他癌的组合物和其制备药物的用途

Country Status (17)

Country Link
US (8) US7101991B2 (https=)
EP (2) EP1545561B1 (https=)
JP (2) JP5127138B2 (https=)
KR (1) KR101142080B1 (https=)
CN (1) CN1703229B (https=)
AT (1) ATE465743T1 (https=)
AU (1) AU2003278028B2 (https=)
CA (1) CA2498026C (https=)
DE (1) DE60332363D1 (https=)
DK (1) DK1545561T3 (https=)
ES (1) ES2345330T3 (https=)
IL (1) IL167621A (https=)
MX (1) MXPA05003551A (https=)
NO (2) NO338310B1 (https=)
NZ (1) NZ538841A (https=)
WO (1) WO2004030660A2 (https=)
ZA (1) ZA200502603B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60332363D1 (de) 2002-10-02 2010-06-10 Univ British Columbia Oligonucleotide zur behandlung von prostatakrebs und anderen krebserkrankungen
US20060188508A1 (en) * 2005-02-17 2006-08-24 Cohen Stanley N Methods and compositions for modulating angiogenesis
US20090264502A1 (en) * 2005-08-25 2009-10-22 Bennett C Frank Compositions and their uses directed to hsp27
JP2009532017A (ja) * 2006-02-10 2009-09-10 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア ＰＴＤ／ＣＰＰＳへのｄｓＲＮＡ結合ドメイン融合体によるｓｉＲＮＡの導入可能な送達
US8242258B2 (en) * 2006-12-03 2012-08-14 Agilent Technologies, Inc. Protecting groups for RNA synthesis
US9381209B2 (en) * 2007-03-05 2016-07-05 The University Of British Columbia Treatment of squamous cell carcinoma with HSP27 antisense oligonucleotides and radiotherapy
CA2680600A1 (en) 2007-03-12 2008-09-18 Antigen Express, Inc. Li-rnai involved li suppression in cancer immunotherapy
CA2656577A1 (en) * 2008-04-14 2009-10-14 The University Of British Columbia Method for evaluation of a cancer
KR20110025863A (ko) * 2008-07-02 2011-03-11 산타리스 팔마 에이/에스 Ｈｓｐ２７을 표적화하는 ｒｎａ 길항제
JP5746968B2 (ja) * 2008-07-18 2015-07-08 オンコジェネックス・テクノロジーズ・インコーポレーテッド アンチセンス製剤
WO2011054811A1 (en) 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
KR101217866B1 (ko) 2010-08-18 2013-01-03 한국원자력의학원 혈관신생 억제용 약학 조성물 및 혈관신생 억제용 활성물질을 스크리닝하는 방법
DE102010056610A1 (de) * 2010-12-31 2012-07-05 Volker A. Erdmann Pharmazeutische Zusammensetzung enthaltend L-DNA
JP5658696B2 (ja) * 2011-02-25 2015-01-28 株式会社ファンケル 皮膚のストレス蓄積度の評価方法
CA2747509C (en) 2011-05-12 2017-07-18 Oncogenex Technologies Inc. Treatment of pulmonary and pleural fibrosis using hsp27 inhibitors
WO2013114339A1 (en) 2012-02-02 2013-08-08 The Universityof British Columbia Combination therapy for cancer using hsp27 inhibitor and egfr tyrosine kinase inhibitors or anti-folates
GB201204785D0 (en) 2012-03-19 2012-05-02 Queen Mary & Westfield College Method for determining prognosis of prostate cancer in a subject
KR101374585B1 (ko) * 2012-05-02 2014-03-17 연세대학교 산학협력단 ＨＳＰ２７ 발현을 억제하는 ｓｈＲＮＡ
US9950001B2 (en) 2012-08-20 2018-04-24 The Regents Of The University Of California Polynucleotides having bioreversible groups
EP3174541A1 (de) 2014-07-28 2017-06-07 Technische Universität Dresden Thymin- und chinazolin-dion-derivate zur hemmung von hsp27
MX2018006527A (es) * 2015-11-30 2018-11-29 Univ British Columbia Inhibidores de oligonucleotidos antisentido (aso) del transportador de monocarboxilato4 (mct4) para su uso como agentes terapeuticos en el tratamiento de cancer.
WO2019050948A1 (en) 2017-09-05 2019-03-14 Regeneron Pharmaceuticals, Inc. ADMINISTRATION OF A GENE EDITION SYSTEM HAVING ONLY ONE RETROVIRAL PARTICLE AND METHODS OF GENERATING AND USING

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2151585A1 (en) * 1992-12-14 1994-06-23 Start Technology Partnership Administration of oligonucleotides antisense to dopamine receptor mrna for diagnosis and treatment of neurological pathologies
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
JPH09176011A (ja) * 1995-12-27 1997-07-08 Kureha Chem Ind Co Ltd Ｈｓｐ２７ファミリーに属するタンパク質のフラボノイド含有合成抑制剤
US20060008448A1 (en) * 1996-06-11 2006-01-12 Minzhen Xu Inhibition of li expression in mammalian cells
JPH107559A (ja) 1996-06-18 1998-01-13 Kureha Chem Ind Co Ltd Ｈｓｐ２７ファミリーに属するタンパク質のベルベリン誘導体含有合成抑制剤
US5962262A (en) 1997-07-25 1999-10-05 Incyte Pharmaceuticals, Inc. Human heat shock 27 like protein
US6703228B1 (en) 1998-09-25 2004-03-09 Massachusetts Institute Of Technology Methods and products related to genotyping and DNA analysis
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
CA2375467C (en) 1999-07-19 2013-10-29 The University Of British Columbia Antisense therapy for hormone-regulated tumors
AU2001249317A1 (en) 2000-03-21 2001-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
EP2301563A3 (en) * 2001-08-23 2011-08-10 Board Of Regents Arizona HSP20 peptides
DE60332363D1 (de) * 2002-10-02 2010-06-10 Univ British Columbia Oligonucleotide zur behandlung von prostatakrebs und anderen krebserkrankungen
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20090264502A1 (en) * 2005-08-25 2009-10-22 Bennett C Frank Compositions and their uses directed to hsp27
US9381209B2 (en) 2007-03-05 2016-07-05 The University Of British Columbia Treatment of squamous cell carcinoma with HSP27 antisense oligonucleotides and radiotherapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Sandrine Horman et al.anti-sense inhibition ofsmall-heat-shock-protein(HSP27)expression in MCF-7mammary-carcinoma cells induces theirspontaneousacquisition of a secretory phenotype.Int.J.Cancer82 4.1999,82(4),574-582.
Sandrine Horman et al.anti-sense inhibition ofsmall-heat-shock-protein(HSP27)expression in MCF-7mammary-carcinoma cells induces theirspontaneousacquisition of a secretory phenotype.Int.J.Cancer82 4.1999,82(4),574-582. *

Also Published As

Publication number Publication date
US7550580B2 (en) 2009-06-23
DK1545561T3 (da) 2010-08-02
US20150232843A1 (en) 2015-08-20
EP1545561A2 (en) 2005-06-29
JP5237996B2 (ja) 2013-07-17
NO338310B1 (no) 2016-08-08
KR20050050111A (ko) 2005-05-27
US9404109B2 (en) 2016-08-02
US7723312B2 (en) 2010-05-25
ATE465743T1 (de) 2010-05-15
AU2003278028B2 (en) 2008-12-18
US7101991B2 (en) 2006-09-05
US20060040886A1 (en) 2006-02-23
EP2216029A2 (en) 2010-08-11
IL167621A (en) 2011-11-30
JP2006503904A (ja) 2006-02-02
CA2498026A1 (en) 2004-04-15
NO20052055L (no) 2005-06-23
US20140315978A1 (en) 2014-10-23
CA2498026C (en) 2015-06-30
NO20160655A1 (no) 2016-04-20
WO2004030660A3 (en) 2004-06-10
JP5127138B2 (ja) 2013-01-23
MXPA05003551A (es) 2005-10-19
US20160326527A1 (en) 2016-11-10
EP1545561B1 (en) 2010-04-28
US9580712B2 (en) 2017-02-28
ZA200502603B (en) 2006-06-28
US20040127441A1 (en) 2004-07-01
JP2010215669A (ja) 2010-09-30
US20060276424A1 (en) 2006-12-07
ES2345330T3 (es) 2010-09-21
KR101142080B1 (ko) 2012-05-03
NZ538841A (en) 2006-10-27
US7847091B2 (en) 2010-12-07
US8772470B1 (en) 2014-07-08
US20090221678A1 (en) 2009-09-03
US9085769B2 (en) 2015-07-21
AU2003278028A1 (en) 2004-04-23
CN1703229A (zh) 2005-11-30
WO2004030660A2 (en) 2004-04-15
EP2216029A3 (en) 2010-12-22
DE60332363D1 (de) 2010-06-10

Similar Documents

Publication Publication Date Title
US9580712B2 (en) Compositions and methods for treatment of prostate and other cancers
JP6730285B2 (ja) Ｒｎａ干渉組成物及び悪性腫瘍のための方法
JP4620585B2 (ja) クラステリンレベルを減少させることによる黒色腫の治療
US12146139B2 (en) Oligonucleotide interference treatments of prostate cancer
US10568901B2 (en) Micro-RNA for the treatment of malignant solid tumors and metastasis
US8722872B2 (en) Compositions and methods for treatment of prostate and other cancers
US20250257360A1 (en) Oligonucleotide interference treatments of prostate cancer
ES2350978T3 (es) Tratamiento del melanoma mediante la reducción de los niveles de clusterina.
JP2023011959A (ja) 医薬組成物
Miyake et al. Antisense oligodeoxynucleotide therapy for prostate cancer targeting antiapoptotic genes involved in the mechanism mediating progression to androgen independence

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110105

Termination date: 20171002